# A multistage mixed-methods evaluation protocol for the national testing response during the COVID-19 pandemic in England

- 4
- 5 Reshania Naidoo<sup>1,2\*</sup>, Ben Lambert<sup>3,4</sup>, Merryn Voysey<sup>5</sup>, Rima Shretta<sup>2</sup>, Claire Keene<sup>2</sup>, Marta Wanat<sup>6</sup>,
- 6 Billie Andersen-Waine<sup>7</sup>, Prabin Dahal<sup>7</sup>, Kasia Stepniewska<sup>7</sup>, Rachel Hounsell<sup>2</sup>, Sassy Molyneux<sup>2</sup>, Emily
- 7 Rowe<sup>1</sup>, Sarah Pinto-Duschinsky<sup>1</sup>, Gulsen Yenidogan<sup>1</sup>, Tom Fowler<sup>8</sup>, Lisa J White<sup>9</sup>, and the EY-Oxford
- 8 Health Analytics Consortium\*\*
- 9
- 10 <sup>1</sup>Ernst & Young (EY) UKI Health Sciences and Wellness, London, UK
- 11 <sup>2</sup>NDM Centre for Global Health Research, Nuffield Department of Medicine, University of Oxford, UK
- 12 <sup>3</sup>Department of Statistics, University of Oxford, UK
- 13 <sup>4</sup>College of Engineering, Mathematics and Physical Sciences, University of Exeter, Exeter, UK
- 14 <sup>5</sup>Oxford Vaccine Group, Department of Paediatrics, University of Oxford, UK
- 15 <sup>6</sup>Nuffield Department of Primary Care Health Sciences, University of Oxford, UK
- 16 <sup>7</sup>Infectious Diseases Data Observatory, Nuffield Department of Medicine, University of Oxford, UK
- 17 <sup>8</sup> UK Health Security Agency
- 18 <sup>9</sup>Big Data Institute, Nuffield Department of Medicine, University of Oxford, UK
- 19
- 20 \*Corresponding author: Reshania Naidoo, email: <u>Reshania.naidoo@ndm.ox.ac.uk</u>
- 21 \*\*The EY-Oxford Health Analytics Consortium membership list is attached in Appendix A
- 22
- 23
- 24
- L-T
- 25
- 26
- 27
- 28
- 29
- 30

#### Abstract 31

#### Introduction 32

33	In 2020, the UK government established a large-scale testing programme to rapidly identify
34	individuals in England who were infected with SARS-CoV-2 and had COVID-19. This
35	comprised part of the UK government's COVID-19 response strategy, to protect those at risk
36	of severe COVID-19 disease and death and to reduce the burden on the health system. To
37	assess the success of this approach, the UK Health Security Agency (UKHSA) commissioned
38	an independent evaluation of the activities delivered by the National Health System (NHS)
39	testing programme in England. The primary purpose of this evaluation will be to capture key
40	learnings from the rollout of testing to different target populations via various testing
41	services between October 2020 and March 2022 and to use these insights to formulate
42	recommendations for future pandemic preparedness strategy. In this protocol, we detail the
43	rationale, approach and study design.

#### Methods and analysis 44

The proposed study involves a stepwise mixed-methods approach, aligned with established 45 methods for the evaluation of complex interventions in health, to retrospectively assess the 46 47 combined impact of key asymptomatic and symptomatic testing services nationally. The research team will first develop a Theory of Change, formulated in collaboration with testing 48 49 service stakeholders, to understand the causal pathways and intended and unintended outcomes of each testing service and explore contextual impacts on each testing service's 50 intended outcomes. Insights gained will help identify indicators to evaluate how the 51 52 combined aims of the testing programme were achieved, using a mixed methods approach.

53	Ethics and dissemination The study protocol was granted ethics approval by the UKHSA
54	Research Ethics and Governance Group (reference NR0347). All relevant ethics guidelines
55	will be followed throughout. Findings arising from this evaluation will be used to inform
56	lessons learnt and recommendations for UKHSA on appropriate pandemic preparedness
57	testing programme designs; findings will also be disseminated in peer-reviewed journals and
58	at academic conferences. This will be the first evaluation to produce a portfolio of evidence
59	in relation to the testing effectiveness and public health impact of the national testing
60	programme in England, encompassing behavioural, economic, equity and public health
61	impacts. These findings will strengthen the evidence base with regards to the effectiveness
62	of COVID-19 testing and identify which aspects are necessary to prioritise in mitigating
63	future pandemic threats when deploying a complex public health intervention such as
64	testing.
64 65	testing. <b>Transparency declaration:</b> The lead author (the manuscript's guarantor) affirms that the
65	<b>Transparency declaration:</b> The lead author (the manuscript's guarantor) affirms that the
65 66	<b>Transparency declaration:</b> The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate and transparent account of the study being reported; no
65 66 67 68	<b>Transparency declaration:</b> The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate and transparent account of the study being reported; no important aspects of the study have been omitted, and any discrepancies from the study as planned have been explained.
65 66 67	<b>Transparency declaration:</b> The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate and transparent account of the study being reported; no important aspects of the study have been omitted, and any discrepancies from the study as
65 66 67 68	<b>Transparency declaration:</b> The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate and transparent account of the study being reported; no important aspects of the study have been omitted, and any discrepancies from the study as planned have been explained.
65 66 67 68 69	Transparency declaration: The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate and transparent account of the study being reported; no important aspects of the study have been omitted, and any discrepancies from the study as planned have been explained. Strengths and limitations of this protocol
65 66 67 68 69 70	Transparency declaration: The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate and transparent account of the study being reported; no important aspects of the study have been omitted, and any discrepancies from the study as planned have been explained. Strengths and limitations of this protocol • Strengths of this mixed methods evaluation protocol include the use of theory-

74 a scarcity of previous relevant research, either in England or appropriate

75 international comparators, warranting the mixed methods evaluation approach we76 will employ.

77 •	To the best of the authors' knowledge, this is the first national-scale evaluation of
78	the COVID-19 testing programme in England to incorporate the broadest scope of
79	testing services, a programme that formed an integral part of the UK pandemic
80	response strategy. The approach proposed could be applied to the evaluation of
81	pandemic responses in other contexts or to other types of interventions.
82 •	Whereas most complex interventions are ideally accompanied by a prospective
83	evaluation design initiated at the time of the intervention or earlier, this study will
84	predominantly comprise a retrospective evaluation and is therefore limited by the
85	quality of existing research and the data available to the research team at the time
86	of conducting the evaluation, within the specified eight-month period allocated by
87	UKHSA. As the UK government is in the process of consolidating data and policy
88	related to the COVID-19 pandemic and subject to an independent inquiry, certain
89	datasets may not be available to the researchers at the time of conducting the
90	evaluation.
91 •	The scope of testing services to be evaluated and the selection of methods has been
92	guided by the study sponsor team within UKHSA and must be achievable within the
93	timeframe of the funding allocated to the study (eight months). Therefore, some

94 trade-offs had to be made in terms of selecting research methods that would be
95 feasible within this time constraint. For future evaluations, a mixed methods
96 approach could be complemented by qualitative interviews with members of the
97 public to gauge their experiences of testing and test-related behaviours, as well as an

- 98 evaluation of other testing services that were out of scope for this research,
- 99 including in prisons, the private sector and the events testing programme.

# 100 Introduction

101	On 11 March 2020, the World Health Organization (WHO) declared COVID-19 a pandemic
102	and exhorted member states to 'test, test, test'.(1) In response to the COVID-19 pandemic,
103	the UK government committed to mass testing, with initial testing commencing in March
104	2020.(2) NHS Test and Trace (NHSTT) was formally established in in May 2020, as a part of
105	the Department of Health and Social Care (DHSC), to lead an 'at scale' national testing and
106	tracing service.(3) The UK Health Security Agency (UKHSA) was established, also as an
107	Executive Agency of DHSC, on 1 April 2021 and was operational on 1 October 2021.(4)
108	UKHSA combines the health protection, clinical and scientific functions formerly carried out
109	by Public Health England (PHE) with the functions of NHSTT and the Joint Biosecurity Centre
110	(JBC).(5)
111	During the initial phases of the pandemic, in the absence of pharmaceutical interventions or
112	a vaccine, testing was seen as a key means to reopen society. The UK government's COVID-
113	19 response strategy was therefore deployed in the context of mitigating the impact of the
114	pandemic and the measures employed to control it on key areas of society, such as

education, protection of livelihoods and preventative and mental health.(6) NHSTT was

tasked with providing mass-scale testing and tracing systems to rapidly identify individuals

with COVID-19 and their close contacts, thereby minimising the spread of the disease.(7)

118 The NHSTT programme had four main stated objectives: 1) to increase the speed and

availability of testing, 2) to identify close contacts of positive cases and require them to

- isolate, 3) to contain local outbreaks via a coordinated response, and 4) to enable the
- 121 government to learn more about the virus and explore ways to ease infection control
- measures as the science developed.(3) The programme, at its scale, was the first of its kind

in the UK and was created and delivered at pace during a period of unprecedented

124	uncertainty.
-----	--------------

125 The testing programme component of NHSTT played an integral role in the government's 126 COVID-19 response through the programme's various testing services. The testing 127 programme sought to work in partnership with national and local public health bodies, local 128 authorities, the NHS, and commercial and academic providers. The delivery of testing for 129 each of the target populations was multi-modal, through combinations of in-person testing, 130 e.g. public regional testing sites and mobile testing units, and via pharmacies and home 131 direct self-test kit deliveries; it was also driven in part by the technology available at the 132 time, e.g. accredited self-sample collection was originally not an option, so physical testing 133 sites were required. The delivery of testing was initially focused on regional and local PCR 134 testing sites, followed by service-specific testing sites, then PCR and LFD home testing was 135 rolled out as evidence accrued that this was a viable approach. These approaches to testing 136 were subject to ongoing revision by policymakers throughout the pandemic, dependent on 137 factors such as changing epidemiological prevalence, the emergence of new variants of 138 concern, e.g. the Delta and Omicron variants, updated scientific evidence and vaccination 139 rollout.(8)

Tests for COVID-19 include those that detect the presence of the SARS-CoV-2 virus and those that detect the presence of antibodies to the virus.(9) Tests for the virus that detect viral nucleic acid, such as polymerase chain reaction (PCR) and loop-mediated isothermal amplification (LAMP), are usually performed in a laboratory. These tests can appear positive beyond the period of infectiousness.(10) Lateral flow devices (LFDs) are test devices that can detect SARS-CoV-2 viral protein (antigen) and represent a more rapid approach to testing.

146	They can also be used for self-testing, although they are less sensitive than nucleic acid-
147	based tests (11) and tend only to appear positive during the period of maximal viral
148	shedding.(12) At the start of the pandemic, only PCR tests were available for testing swabs
149	from suspected cases of COVID-19; however, LFDs for COVID-19 were rapidly developed and
150	being evaluated for use by mid-2020.(13) LFDs were initially rolled out for asymptomatic
151	testing, followed by a confirmatory PCR test in the case of a positive LFD result.
152	The overall success and effectiveness of any national COVID-19 testing service is dependent
153	on multiple contextual factors and the combined impacts of the various testing services.
154	From a public health perspective, increased testing has been shown to result in reduced
155	transmission of SARS-CoV-2 and associated hospitalisations and mortality.(14-18)
156	Behavioural responses to testing strategies are dependent on public awareness and trust,
157	with adherence to testing policy shown to be driven by perceptions of disease risk and
158	socioeconomic factors.(19) From an equity perspective, COVID-19 testing has been found to
159	exacerbate existing health inequities, with disparities in access to testing for individuals
160	from ethnic minority backgrounds and those living in socially deprived areas.(20) The
161	economic impact of testing can be assessed via cost-effectiveness evaluations of testing
162	strategies, including testing unit costs, operational deployment costs and, on a macro-
163	economic level, quantifying the economic productivity gained from shortened isolation
164	periods and savings to the taxpayer.(21, 22)
165	UKHSA has appointed a consortium from Ernst & Young LLP in partnership with academics
166	from the University of Oxford, contracted through Oxford University Innovation Limited, to
167	carry out an evaluation of the testing programme; the evaluation will take eight months.
168	This consortium (hereafter referred to as 'the evaluation consortium') will undertake an

169	independent evaluation of the testing capabilities delivered by the national COVID-19
170	testing programme in England from October 2020 to March 2022 (hereafter referred to as
171	'the evaluation'), with a focus on public health outcomes. This evaluation will seek to
172	capture key learnings from the rollout of testing to the various target populations via the
173	different testing services during this period. The insights gained will inform the formulation
174	of key considerations and recommendations for future pandemic preparedness. Owing to
175	the complexity and rapidly evolving nature of the testing response, no evaluation of the
176	national testing service in England, utilising a mixed methods approach, has been conducted
177	to date.

# 178 **Testing services in scope**

The evaluation consortium and UKHSA has decided to conduct an overarching evaluation of the national COVID-19 testing programme in England by assessing the combined impact of the asymptomatic and symptomatic testing services. A major component of this will be an evaluation of the universal testing service. This will be complemented by 'deep-dive' evaluations of three 'priority' testing services (see table 1 for further details):

- Schools (secondary school pupils aged 11 to 18 years)
- Adult social care (staff and residents in care homes)
- 186 Healthcare workers

187 These four services have been included to ensure a broad spectrum of testing populations in 188 England will be evaluated within the given timeframe, i.e. high volumes (universal testing), 189 high-contact groups (schools) and high-risk groups (care homes and healthcare workers), to

- 190 best reflect the challenges faced during the pandemic and to balance the findings and
- 191 recommendations for future pandemics.
- 192 Table 1. Overview of the testing services of the COVID-19 testing programme identified as
- 193 within scope for this evaluation

#### 194

Testing service	Purpose of testing
Schools	Testing of staff and students to prevent transmission within schools and, as they are a high-contact group, within the community and to allow schools to continue functioning as normally as possible
Adult social care	Testing to prevent outbreaks in vulnerable populations (predominantly those in care homes and those receiving domiciliary care)
Healthcare	Testing of NHS staff and patients to reduce the risk of transmission within hospital and other healthcare settings, which could then impact transmission in the community
Universal testing	Rapid, asymptomatic, at-home testing with LFDs that were made available to the general public to enable faster detection of cases, thereby allowing more rapid self-isolation

195

196 The evaluation will follow a hypothesis-led approach, with three key hypotheses developed;

197 based on these hypotheses, the evaluation will seek to answer several research questions

198 (box 1).

199 Box 1. Hypotheses developed and research questions to be explored in the evaluation

**Hypothesis 1:** testing services aimed at protecting high-risk groups, e.g. people in care homes and healthcare workers, led to a reduction in hospitalisations and deaths in these risk groups

**Hypothesis 2:** testing services aimed at high-contact groups, e.g. children in schools, led to a reduction in hospitalisations and deaths in the general population

**Hypothesis 3:** testing services aimed at increasing access to and eligibility for testing and targeting disproportionately impacted groups, e.g. the universal testing service, led to increased testing uptake in these populations

# **Research questions:**

- How was the national COVID-19 testing programme delivered and what factors affected this?
- 2. What were the barriers and facilitators to access, use and deliver the programme?
- 3. What were the costs and the cost-effectiveness of the programme?
- 4. For the universal testing service:
  - a. Did the diversity of those reporting test results increase?
  - b. Did the barriers and facilitators for testing, reporting and acting on a result change?
- 5. For each testing service:
  - a. Did the service achieve UKHSA's intended aims and purposes of the service?
  - b. Was the service cost-effective?
  - c. If testing were to be implemented again, what are the barriers and facilitators to increase access, use and delivery of tests?

# 201 Methodology

# 202 **Principles guiding the evaluation**

- 203 The testing programme can be considered to be a complex public health intervention due to
- the complexity of the intervention design, which evolved over time according to policy
- changes and the evolving disease context within which it was implemented.(23) Therefore,
- 206 this retrospective evaluation will employ a mixed methods approach, utilising existing
- 207 frameworks that have previously been applied to the evaluation of complex interventions,
- 208 being broadly divided into process, outcome and impact evaluation components.(24-27)
- 209 The evaluation will consist of a phased process:
- A scoping phase, to develop a Theory of Change (ToC), evaluation aims and research
   questions
- A design phase, to agree the mixed methods approach to the evaluation and confirm
   process, outcome and impact indicators
- A conduct phase, to collect, review and synthesise data
- A recommend phase, during which findings and data will be triangulated to form
   conclusions and recommendations

217 The Medical Research Council (MRC) framework for process evaluation details three key

- 218 interrelated components required as part of any evaluation of a complex public health
- 219 process: implementation, mechanisms of impact, and context.(27) The ToC approach(28, 29)
- 220 a theory of how and why an initiative works will therefore be used to map the causal
- 221 pathways for each of the testing services, as this approach lends itself to understanding
- 222 complex interventions with multiple causal pathways.(30) The ToC framework will be used

to understand the causal pathways and intended and unintended outcomes of each service,
as well as exploring the effect of context on each individual testing service's intended
outcomes.

- 226 The ToCs will be formulated utilising existing evidence provided by UKHSA and will be
- subject to further refinement following interviews with UKHSA policy and operational
- stakeholders. Insights from existing UK government-commissioned evidence in the form of
- 229 previous COVID-19 service-specific testing evaluations and pilot testing programme data will
- 230 be utilised where possible to avoid duplication of work. Owing to the unpredictability of
- evaluating complex interventions such as this, sufficient flexibility will be allowed within the
- research design to allow emerging research questions to be addressed.(27)
- 233 A comprehensive ToC for each of the testing services in scope will subsequently inform
- process and outcome indicators (table 2) that will be used to assess each service, address
- the research questions and determine how well each service met its objectives and
- intended purpose.(31) Based on data availability and granularity, these indicators will be
- further refined based on what is achievable within the evaluation timeframe.
- 238 The indicators will be categorised as follows:
- Process and output indicators: how did the delivery and uptake of the service
- 240 compare with what was planned over time, and what factors affected this?
- Outcome indicators: what was the effectiveness of each service in terms of its
   intended outcomes?
- Impact indicators: what were the broader economic and societal impacts? What
   were the overall impacts on minimising transmission while limiting harm?

- A gap analysis will also be performed during the 'conduct' stage to determine whether any
- crucial data, research or information is unavailable within the existing literature or data
- sources provided by UKHSA and whether subsequent adjustment of the research questions
- 248 or descoping is required. This will be decided through a participatory consultation approach
- 249 with key UKHSA stakeholders.
- 250 Table 2. Example of potential evaluation indicators for the overall national testing
- 251 programme

Indicator type	Indicator description	Proposed method type to evaluate the indicator
PROCESS/OUTPUT	Average percentage of LFDs distributed that were reported over the 18-month time period	Statistical
	Average percentage of PCR tests registered that were reported over the 18-month time period	Statistical
	Number of LFDs distributed over the 18-month time period	Statistical
	Number of PCR tests registered over the 18-month time period (separated by Pillars 1 and 2* and total)	Statistical
	Cost per LFD conducted over the 18-month time period	Economic
	Cost per PCR test conducted over the 18-month time period	Economic
	Total financial cost of the testing service over the 18-month time period	Economic
	Total number of tests reported per week	Statistical
	Reported test positivity of LFD and PCR by indices of multiple deprivation (IMD) decile before and after rollout of universal testing	Statistical
	Ratio of mean number of reported tests in the upper income decile: the lowest income decile	Statistical
OUTCOME	Number of hospitalisations averted with different assumptions of reductions in new cases	Economic
	Number of deaths averted with different assumptions of reductions in new cases	Economic
	Cost savings from hospitalisations averted with different assumptions of reductions in new cases	Economic
	What were the barriers and facilitators to taking a test, reporting a test and acting on a positive test result?	Rapid scoping review
IMPACT	Cost per quality-adjusted life-year (QALY) gained with different assumptions of reductions in new cases	Economic

252 \*Pillar 1: swab testing for SARS-CoV-2 in UKHSA laboratories and NHS hospitals for those with a clinical need and for health

and care workers; Pillar 2: swab testing for SARS-CoV-2 in the wider population, through commercial partnerships, either

254 processed in a laboratory or more rapidly via LFDs

# 255 Mixed methods approach to be used in the evaluation

256	A convergent parallel mixed-methods approach will be taken to provide a more holistic
257	understanding of the testing programme, allowing the researchers to capture any
258	unanticipated aspects of testing that may be relevant to the research questions and to
259	explain the quantitative findings.(32)
260	Findings from the rapid scoping review will be triangulated with the results of the statistical
261	and economic analyses and fed back into the developing ToCs, to refine and explain the
262	indicators, address the hypotheses and help form the recommendations for each testing
263	service during the various evaluation phases. In addition, findings across each of the four
264	testing services will be compared, with the aim of identifying universal as well as service-
265	specific barriers and facilitators to testing, reporting and self-isolation following a positive
266	test result.

The ToCs will be populated in a collaborative manner, enabling the quantitative and qualitative research teams between them to define and align the process and outcome indicators for each testing service. Each team will conduct research concurrently for the various testing services and will communicate their findings at weekly meetings, allowing for emerging findings to be discussed and explored further if deemed necessary. Findings will also be synthesised across the testing services to inform programme-level insights to meet the programme-level research aims and inform the overarching ToC and indicators.

# 274 Qualitative data analysis: rapid scoping review of testing behaviours

A rapid scoping review will be conducted to evaluate the barriers and facilitators to

engaging with COVID-19 testing, reporting results and self-isolating following a positive

277	result in the United Kingdom. This review will aim to 1) provide a summary of the research
278	undertaken on this topic available both in the UKHSA grey literature and in the wider
279	academic literature, 2) identify gaps in research efforts, and 3) provide an overview of key
280	barriers and facilitators for engagement with each testing service, as well for the overall
281	testing programme. A scoping study approach has been selected as the method to
282	synthesise the broad knowledge base on this topic, owing to the large volume of
283	heterogenous literature available and to accommodate the time constraints of the
284	commissioned evaluation.(33) The scoping review will be conducted adhering to the 2005
285	Arksey and O'Malley framework, (34) incorporating the adaptations proposed in 2010 by
286	Levac and colleagues on iterative study selection and stakeholder consultation (35) and also
287	using the 2015 Joanna Briggs Institute guidance on conducting scoping reviews.(36) The
288	findings will be reported according to the standardised PRISMA-ScR (Preferred Reporting
289	Items for Systematic reviews and Meta-Analyses extension for Scoping Reviews)
290	checklist.(37)

# 291 Search strategy and the selection of evidence

A wide search strategy has been developed, using key phrases from relevant articles(34) (see table 3 for categories and example terms). This will be used to identify literature that describes behaviour around COVID-19 testing, reporting and self-isolation in the UK during the COVID-19 pandemic. The search strategy will be adapted for each database and information source that is searched and will be refined based on key words in sources identified during the search.

298

299

## 300

301 Table 3. Search categories and examples of search terms

#### 302

303

304

305

Category	Example search terms
COVID-19	COVID* OR corona OR coronavirus OR SARS-CoV-2 OR "SARS CoV 2" OR "SARS CoV-2" OR
	SARS-CoV2 OR SARSCoV2 OR "Severe Acute Respiratory Syndrome Coronavirus 2" OR
	"Severe Acute Respiratory Syndrome Corona Virus 2" OR 2019-nCoV
	AND
Key activities	test* OR screen* OR RT-PCR OR PCR OR "polymerase chain reaction" OR "lateral flow" OR
	"lateral flow device *" OR "lateral flow assay *" OR LFD OR self-test * OR "test and trace" O
	"contact trac*" OR surveillance OR POCT OR report* OR self-report* OR selfreport* OR
	"test positive"" OR "testing positive" OR result* OR "self-isolation" OR "self isolation" OR
	isolat* OR containment OR reopening OR re-opening OR mitigat* OR flatten*
	AND
Behaviour,	knowledge OR understand* OR attitude* OR perception* OR perceive OR belief* OR
-	believ* OR expectation* OR trust OR willing* OR intention* OR behaviour* OR behavior*
facilitators	OR practice* OR enact* OR engag* OR adher* OR complian* OR comply OR experience*
	OR view* OR motivation* OR barrier* OR block* OR challeng* OR difficult* OR facilitat* C
Key activities Behaviour, barriers and facilitators Research methods Geographic setting	enabl* OR access* OR feasib* OR accept* OR uptake
	AND
Research	qualitative* OR interview* OR FGD OR "focus group*" OR survey* OR questionnaire* OR
	mixed-method* OR "mixed method*" OR ethnograph* OR theme OR thematic* OR
methods	"grounded theory" OR "content analysis" OR field-work OR "field work" OR selfreport* OF
	self-report* OR "self report*" OR view* OR experience* OR hermeneutic OR
	phenomenolog*
	AND
Geographic	"United Kingdom" OR UK OR England OR Ireland OR Irish OR Scot* OR Wales OR Britain O
	"United Kingdom" OR UK OR England OR Ireland OR Irish OR Scot* OR Wales OR Britain O British OR NHS OR "National Health Service*" OR UKHSA OR "United Kingdom Health
	"United Kingdom" OR UK OR England OR Ireland OR Irish OR Scot* OR Wales OR Britain O British OR NHS OR "National Health Service*" OR UKHSA OR "United Kingdom Health Security Agency" OR "UK Health Security Agency" OR "Channel Island*" OR London OR

306 (including grey literature), as well as reports and guidance documentation. Research,

307 published from 1 January 2020 onwards and in English, will be included in the review if they

308 focus on one or more of the following three behaviours: undertaking a test, reporting a test

- 309 result and self-isolating following a positive result, symptoms or a positive contact (see table
- 310 4 for search limits and eligibility criteria).
- Table 4. Summary of the search parameters and limits as well as the inclusion and exclusion
- 312 criteria, categorised according to the 'population, context, concept' search framework. (34,
- 313 36)
- 314 Click or tap here to enter text.

	Inclusion	Exclusion
SEARCH LIMITS		
Language	Published in English	Published in languages other than English
Dates	Published between 1 January 2020 and the search date (the database search was conducted on 7 November 2022 and the UKHSA documents were received throughout September to December 2022)	Published before 2020
Methods	Qualitative or mixed-methods studies; quantitative surveys	Quantitative studies only reporting associations between demographic variables and behavioural outcomes
ELIGIBILITY		
Literature	Journal articles, peer-reviewed material, articles under review, published books and book chapters, other academic research, research commissioned by governments, unpublished reports	Opinion or statement pieces, magazine articles, blog posts
Population	England, Northern Ireland, Scotland, Wales and the islands making up the British Isles; multi-country studies were included if they included one of these settings	Countries outside the UK, including the Republic of Ireland
Concept (key activities)	<ul> <li>Descriptions of individuals' behaviour and/or barriers to testing and/or facilitators to testing with regards to the following key activities: <ul> <li>Antigen testing for COVID-19 (with a focus on LFDs, but including LAMP and PCR testing)</li> <li>Reporting test results</li> <li>Isolating (with a focus on isolating due to a positive COVID-19 test result, but including isolating after being identified as a close contact of a COVID-19-positive case)</li> </ul> </li> <li>The description of behaviours included associations of survey responses with behaviour or intention to test, report or isolate</li> </ul>	Descriptions of testing, reporting or self-isolation but not the behaviour associated with them, e.g. describes the sensitivity of a specific test Descriptions of testing for antibodies Descriptions of the barriers or facilitators to self-isolation in the context of social distancing, self- isolation if symptomatic or traveller isolation (hotel quarantine) Descriptions of associations of demographic factors with behaviour or intention to test, report or isolate Testing, reporting results or self- isolation after a positive result in the context of other diseases Descriptions of facilitators or

barriers to other COVID-19-related
behaviours, such as vaccination or
social distancing
Descriptions of the impact of
testing/reporting/self-isolation on
behaviour
Knowledge, attitudes or perception
in relation to COVID-19 itself

315

316

## 317 Stakeholder-identified supplementary data

- 318 UKHSA has identified a repository of data and documentation, comprising more than 5000
- reports and internal documents, that may be of potential relevance to the evaluation. Upon
- 320 commencement of the evaluation, and if a review of the documents highlights further
- 321 potentially relevant sources, additional documentation will be requested by the evaluation
- 322 consortium. This documentation will be searched for evidence that supports the
- 323 consortium's efforts to understand how the testing services were intended to work, how
- 324 they were experienced and any prior measurement of their effectiveness. Supplementary
- 325 documents to be provided by UKHSA could include:
- 326 Testing guidance published by UKHSA
- 327 Testing process documentation
- 328 Business cases
- Primary qualitative or quantitative research (including behavioural studies)
- Documentation involving reporting, managing or measuring the testing programme
- Previous evaluations of testing services

- 332 Once all of the publicly available data have been screened, these stakeholder-identified
- 333 sources will also be reviewed for inclusion.

### 334 Stakeholder consultation

- 335 Stakeholder engagement is considered useful for adding methodological rigour to scoping
- 336 studies. (35) Therefore, stakeholders from the evaluation sponsor team within UKHSA will be
- 337 consulted to help identify additional sources of published and unpublished evidence
- 338 (described above in 'Supplementary Data') and offer perspective and validate the findings.
- Additional sources identified in this way will be included in the scoping review as
- 340 'stakeholder-identified studies', (38) and insights from these conversations with stakeholders

341 will be anonymised and incorporated into the discussion of the scoping review results. Due

- to the rapid turnover of testing programme staff members, the availability of stakeholders
- that the research team will be able to interview is limited. However, the research team has
- been provided with the names of at least ten policy staff per testing service to interview as

345 part of the stakeholder consultation. This list of names was provided by the funder.

346 Ethics Committee approval for this research has been granted on the basis that informed 347 consent be sought prior to engaging with any UKHSA stakeholders and that anonymity will 348 be preserved in our write-up of the findings. To preserve anonymity, robust measures will 349 be implemented, including the development of pseudonyms or codes for participants, secure storage of data on UKHSA laptops and careful handling of information during data 350 351 analysis and reporting. The anonymity preservation strategy has been discussed and refined 352 in collaboration with the study sponsor (UKHSA) and their stakeholders, prior to ethics 353 approval being granted.

## 354 Data extraction, charting and synthesis

355	Data extracted from each evidence source will include study metadata (authors, title, year
356	of publication/dissemination, publication stage, country, participant characteristics and
357	methods), the setting (testing service and key activity), and information about the
358	perceptions, experiences and the barriers and facilitators to each of the key activities
359	(testing, reporting and isolating).
360	All sources will be collated, uploaded into $\Box$ Rayyan, and duplicates removed.(39) Following
361	an initial screening pilot to refine the eligibility criteria, titles and abstracts will then be
362	screened by two reviewers for assessment against the refined inclusion criteria. A sample of
363	$\geq$ 20% will be reviewed by a third reviewer to ensure consistency of inclusion.(35) The inter-
364	rater agreement will then be calculated for the final list using Gwet's first-order agreement
365	coefficient (AC1). (40) Potentially relevant sources will be extracted fully and then assessed
366	against the inclusion criteria. Any disagreements will be resolved through discussion, and
367	with an additional reviewer if no consensus is reached. The same process will be undertaken
368	for the supplementary data.

369 Once all the data have been extracted and assessed against the inclusion criteria, we will

- 370 synthesise the data thematically. This process will be repeated for each testing service.
- 371 Given the rapid timelines, the aim of the work and the scoping study methodology guidance,
- the included publications will not be assessed for quality.

# 373 Quantitative data analysis: statistical methods

## 374 Data collection

375	Quantitative data will be obtained via the secretariat of the study sponsor within UKHSA,
376	existing UKHSA repositories, the UK Office for National Statistics (ONS), NHS Digital and
377	Public Health Scotland; by applying directly to various holders of non-public datasets; and
378	from other public sources of data where available, such as ISARIC (International Severe
379	Acute Respiratory and Emerging Infection Consortium). General datasets will include SARS-
380	CoV-2 seroprevalence surveys; COVID-19 vaccination data; testing coverage data; and
381	COVID-19 cases, hospitalisations and deaths.

### 382 Data analysis

- 383 The data will be analysed with the aim of 1) providing summaries of indicators identified in
- 384 the ToCs, in relation to the implementation of each testing service, to better understand the

extent and reach of each service and validate findings from the rapid scoping review in

relation to behaviours; and 2) providing estimates of the impact of each testing service,

387 which will feed into the cost-effectiveness evaluations. Service-specific statistical

388 approaches will be developed for each of the four testing services.

389 Specified primary outcome indicators will be defined for each testing service, as defined in

390 the ToCs. Outcomes and appropriate counterfactual comparators will be defined,

391 contingent on obtaining access to relevant data sources; these definitions may be refined

392 using an iterative process based on concurrent analysis of qualitative data from the rapid

393 scoping review. For each testing service, a regression-based approach(24) will be

undertaken together with analysis of data at the local authority level (or, if the data allow, at

- 395 a finer spatial aggregation), accounting for potential confounding factors such as age, sex
- and ethnicity profiles, as well as indicators of deprivation, population density and relevant
- 397 chronic illnesses. If determined to be relevant, in collaboration with UKHSA stakeholders,

- 398 predictors of engagement with health services, such as vaccination uptake or access to
- 399 internet services, will also be included.
- 400 Where available, reported case and prevalence data at the lower tier local authority (LTLA)
- level will be combined to determine true case-detection ratios, defined as the percentage of 401
- 402 all true cases that were captured by the national testing programme, using the statistical
- 403 debiasing methodology described by Nicholson et al.(41)

#### Quantitative data analysis: economic evaluation methods 404

#### Data collection 405

406	The economic analyses will primarily comprise cost-effectiveness analyses, adopting a
407	provider perspective, incorporating costs to the NHS and to local authorities. For the schools
408	testing service analysis, a societal perspective will be adopted to quantify potential
409	productivity losses. A rapid literature review of publicly available economic data will be
410	conducted using keyword searches of scientific databases, as well as a search of the grey
411	literature using Google Scholar. Data relating to the volumes of tests distributed to the
412	various testing services and the associated costs will be obtained from UKHSA. Data relating
413	to payments made to individuals who were isolating, and other payments made, will be
414	obtained from DHSC. Costs will be apportioned to the four testing services according to the
415	volumes of tests distributed. The costs of hospitalisations will be obtained from the National
416	Schedule of NHS Costs 2020/21.(42)

#### 417 Data analysis

418 The data will be analysed with the aim of 1) providing an estimate of the costs for each

testing service and 2) providing estimates of the value for money of each testing service. 419

420	The outcome measure of quality-adjusted life-years (QALYs) gained will be used for the
421	economic analyses. The National Institute for Health and Care Excellence (NICE) defines a
422	QALY as 'a measure of the state of health of a person or group in which the benefits, in
423	terms of length of life, are adjusted to reflect the quality of life. One QALY is equal to 1 year
424	of life in perfect health. QALYs are calculated by estimating the years of life remaining for a
425	patient following a particular treatment or intervention and weighting each year with a
426	quality-of-life score (on a 0 to 1 scale)'.(43) The cost per QALY gained is a critical value that
427	can be used to determine whether an intervention is cost-effective and is used by NICE to
428	determine whether a proposed new treatment can be covered by the NHS. We will use a
429	value of GBP 70,000 as the willingness to pay threshold for interventions for COVID-19,
430	based on HM Treasury's Green Book (2022).(44) This means that an intervention that costs
431	less than GBP 70,000 per QALY gained can be considered cost-effective. In any graphs
432	produced, we will also indicate the NICE willingness to pay threshold of GBP 30,000, for
433	reference. QALY weights will be obtained from the relevant literature. Sensitivity analyses
434	will be conducted to test the outcomes against the assumptions, using ranges of estimates
435	from the statistical analyses and the literature, for each of the testing services.

# 436 **Data management plan**

All individuals on the research team will have UK government Baseline Personnel Security
Standard clearance.(45) All 'official-sensitive' data will be accessed via official, UKHSAapproved secure portals and secure UKHSA laptops. All data to be used in the proposed
evaluation will be obtained from UKHSA, allied UK government bodies, such as NHS Digital
and the Office for National Statistics (ONS), and independent research organisations.

442

# 443 **Discussion**

444	The national COVID-19 testing programme in England was rapidly set up, scaled, and
445	adapted over time in response to emerging knowledge about COVID-19 transmission,
446	severity and the availability of other public health interventions, such as vaccination. As a
447	result, ongoing monitoring and evaluation of testing as a public health intervention and its
448	effectiveness was not uniformly implemented. This evaluation will therefore aim to
449	retrospectively evaluate the national testing programme in England as a whole, with a deep
450	dive into the schools, adult social care, healthcare worker and universal testing services,
451	using a mixed-methods approach. We believe that the combined strengths of quantitative
452	and qualitative approaches are necessary to evaluate such a complex intervention and will
453	allow for a broader spectrum of insights and triangulation to inform future learnings.
454	For the purpose of this evaluation, alongside a high-level evaluation of the national testing
455	programme as a whole, we have chosen to narrow our scope to conduct deep dives into
456	four testing services to reflect the spectrum of the impact of testing on both high-risk and
457	high-contact populations and to generate learnings that will be of most value, within the
458	constraints of the evaluation time period.
459	To the best of the authors' knowledge, this evaluation will be the first of its kind to produce
460	a portfolio of evidence on testing effectiveness and public health impact for a nationally
461	deployed testing service, focusing on the behavioural, economic, equity and public health

462 impacts. The findings of the evaluation are expected to strengthen the evidence base in

relation to COVID-19 testing and identify which aspects when deploying a complex public

- 464 health intervention, such as testing, will be necessary for decision-makers to prioritise when
- 465 mitigating future pandemic threats.

## 466 **Funding statement**

- 467 This study will be funded by the Secretary of State for Health and Social Care acting as part
- 468 of the Crown through the UK Health Security Agency (UKHSA), reference number
- 469 C80260/PRO5331.

# 470 Ethics statement

- 471 This study protocol has been granted ethics approval by the UKHSA Research Ethics and
- 472 Governance Group (reference NR0347). All relevant ethics guidelines have been followed.
- 473 Should the research approach or methods change following this version of the protocol, the
- 474 UKHSA Research Ethics and Governance Group will be notified and the appropriate ethics

475 guidelines followed.

# 476 **Disclaimer**

- This protocol represents research in progress, commissioned and funded by UKHSA, to be
- 478 performed between August 2022 and March 2023. The scope and depth of testing services
- 479 covered by this research were pre-agreed with UKHSA and were limited to the availability
- 480 and provision of data available at the time this protocol was written. The corresponding
- 481 author has the right to grant on behalf of all authors, and does grant on behalf of all
- authors, an exclusive licence (or non-exclusive for government employees) on a worldwide
- basis to the BMJ Publishing Group Ltd to permit this article (if accepted) to be published in
- 484 BMJ editions and any other BMJ Publishing Group Ltd products and sublicences such use

- 485 and exploit all subsidiary rights, as set out in the licence. No patients or members of the
- 486 public were involved in this research.

# 487 Acknowledgements

- 488 Scientific writing assistance and editorial support was provided by Adam Bodley, according
- to Good Publication Practice guidelines. The authors would like to acknowledge the efforts
- 490 of the UKHSA Scientific Advisory Group, who provided peer review and approval of the
- 491 study protocol on behalf of the funder.

# 492 **Competing interests statement**

- 493 All authors have completed the ICMJE uniform disclosure form at
- 494 www.icmje.org/coi\_disclosure.pdf and declare that all authors had financial support from
- the UK Health Security Agency (UKHSA) for the submitted work; Ernst & Young LLP London
- 496 has previously received payment for consultancy and advisory work on the NHS Test and
- 497 Trace response from the UK Department of Health and Social Care, prior to the
- 498 establishment of the UK Health Security Agency. There are no other relationships or
- 499 activities that have or could appear to have influenced the submitted work.

500

501

- 503
- 504
- 505
- 506
- 507
- 508

# 509 **References**

510	1. World Health Organization. WHO Director-General's opening remarks at the media briefing
511	on COVID-19 - 16 March 2020: World Health Organization; 2020 [Available from:
512	https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-
513	<u>the-media-briefing-on-covid-1916-march-2020</u> .
514	2. Department of Health and Social Care. Coronavirus (COVID-19): scaling up our testing
515	programmes 2020 [Available from: <u>https://www.gov.uk/government/publications/coronavirus-</u>
516	covid-19-scaling-up-testing-programmes/coronavirus-covid-19-scaling-up-our-testing-programmes.
517	3. Department of Health and Social Care. Government launches NHS Test and Trace service
518	London: HM Government; 2020 [Available from:
519	https://www.gov.uk/government/news/government-launches-nhs-test-and-trace-service.
520	4. UK Health Security Agency. UKHSA Annual Report and Accounts 2021-2022. London: HMSO;
521	2023. Available from:
522	https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file_
523	/1131855/UKHSA Annual Report 21 22 FINAL.pdf.
524	5. UK Health Security Agency. Test and Trace: overarching privacy notice 2021 [Available from:
525	https://www.gov.uk/government/publications/nhs-test-and-trace-privacy-information/test-and-
526	trace-overarching-privacy-notice.
527	6. UK Cabinet Office. Our plan to rebuild: The UK Government's COVID-19 recovery strategy
528	2020 [Available from: https://www.gov.uk/government/publications/our-plan-to-rebuild-the-uk-
529	governments-covid-19-recovery-strategy.
530	7. SAGE. Thirty-second SAGE meeting on Covid-19, 1 May 2020. 2020.
531	8. UK Health Security Agency. NHS Test and Trace statistics (England): methodology 2022
532	[Available from: https://www.gov.uk/government/publications/nhs-test-and-trace-statistics-
533	england-methodology/nhs-test-and-trace-statistics-england-methodology.
534	9. Jarrom D, Elston L, Washington J, Prettyjohns M, Cann K, Myles S, Groves P. Effectiveness of
535	tests to detect the presence of SARS-CoV-2 virus, and antibodies to SARS-CoV-2, to inform COVID-19
536	diagnosis: a rapid systematic review. BMJ Evid Based Med. 2022;27(1):33-45.
537	10. Teymouri M, Mollazadeh S, Mortazavi H, Naderi Ghale-Noie Z, Keyvani V, Aghababaei F, et
538	al. Recent advances and challenges of RT-PCR tests for the diagnosis of COVID-19. Pathol Res Pract.
539	2021;221:153443.
540	11. Leber W, Lammel O, Siebenhofer A, Redlberger-Fritz M, Panovska-Griffiths J, Czypionka T.
541	Comparing the diagnostic accuracy of point-of-care lateral flow antigen testing for SARS-CoV-2 with
542	RT-PCR in primary care (REAP-2). EClinicalMedicine. 2021;38:101011.
543	12. Geddes L. Vaccines Work [Internet]: Gavi, The Vaccine Alliance. 2022. [13 March 2023].
544	Available from: https://www.gavi.org/vaccineswork/infectious-period-are-cuts-covid-19-isolation-
545	times-good-idea.
546	13. Peto T. COVID-19: Rapid antigen detection for SARS-CoV-2 by lateral flow assay: A national
547	systematic evaluation of sensitivity and specificity for mass-testing. EClinicalMedicine.
548	2021;36:100924.
549	14. Mercer TR, Salit M. Testing at scale during the COVID-19 pandemic. Nature Reviews
550	Genetics. 2021;22(7):415-26.
551	15. Di Bari M, Balzi D, Carreras G, Onder G. Extensive Testing May Reduce COVID-19 Mortality: A
552	Lesson From Northern Italy. Front Med (Lausanne). 2020;7:402.
553	16. Rannan-Eliya RP, Wijemunige N, Gunawardana J, Amarasinghe SN, Sivagnanam I, Fonseka S,
554	et al. Increased Intensity Of PCR Testing Reduced COVID-19 Transmission Within Countries During
555	The First Pandemic Wave. Health Aff (Millwood). 2021;40(1):70-81.
556	17. Liang LL, Tseng CH, Ho HJ, Wu CY. Covid-19 mortality is negatively associated with test
557	number and government effectiveness. Sci Rep. 2020;10(1):12567.
558	18. Liverpool University. Liverpool Covid-SMART Community Testing Pilot. Liverpool: Liverpool
559	University; 2021.

560 19. Thorneloe RJ, Clarke EN, Arden MA. Adherence to behaviours associated with the test, trace, and isolate system: an analysis using the theoretical domains framework. BMC Public Health. 561 562 2022;22(1):567. 563 20. Public Health England. Disparities in the risk and outcomes of COVID-19. London: Public 564 Health England; 2020. 565 21. Du Z, Pandey A, Bai Y, Fitzpatrick MC, Chinazzi M, Pastore y Piontti A, et al. Comparative 566 cost-effectiveness of SARS-CoV-2 testing strategies in the USA: a modelling study. The Lancet Public 567 Health. 2021;6(3):e184-e91. 568 22. lacobucci G, Coombes R. Covid-19: Government plans to spend £100bn on expanding testing 569 to 10 million a day. BMJ. 2020;370:m3520. 570 Petticrew M. When are complex interventions 'complex'? When are simple interventions 23. 571 'simple'? European Journal of Public Health. 2011;21(4):397-8. 572 24. HM Treasury. Magenta Book - Central Government guidance on evaluation. London: HM 573 Treasury; 2020. 574 25. Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. Framework for the 575 development and evaluation of complex interventions: gap analysis, workshop and consultation-576 informed update. Health Technol Assess. 2021;25(57):1-132. 577 Skivington K, Matthews L, Simpson SA, Craig P, Baird J, Blazeby JM, et al. A new framework 26. 578 for developing and evaluating complex interventions: update of Medical Research Council guidance. 579 BMJ. 2021;374:n2061. 580 Moore GF, Audrey S, Barker M, Bond L, Bonell C, Hardeman W, et al. Process evaluation of 27. 581 complex interventions: Medical Research Council guidance. BMJ. 2015;350:h1258. 582 28. Aspen Institute Roundtable on Community Change. Community Change: Theories, Practice, 583 and Evidence. Edited by Karen Fulbright-Anderson and Patricia Auspos, editor. Washington D.C.: 584 Aspen Institute; 2006. 585 29. De Silva MJ, Breuer E, Lee L, Asher L, Chowdhary N, Lund C, Patel V. Theory of Change: a 586 theory-driven approach to enhance the Medical Research Council's framework for complex 587 interventions. Trials. 2014;15:267. 588 30. Blamey A, Mackenzie M. Theories of Change and Realistic Evaluation:Peas in a Pod or Apples 589 and Oranges? Evaluation. 2007;13(4):439-55. 590 Funnell SC, Rogers PJ. Purposeful Program Theory: Effective Use of Theories of Change and 31. 591 Logic Models: Wiley; 2011. 592 32. Creswell JW. Research Design: Qualitative, Quantitative, and Mixed Methods Approaches: 593 SAGE Publications: 2014. 594 33. Tricco AC, Lillie E, Zarin W, O'Brien K, Colquhoun H, Kastner M, et al. A scoping review on the 595 conduct and reporting of scoping reviews. BMC Med Res Methodol. 2016;16:15. 596 34. Arksey H, O'Malley L. Scoping studies: towards a methodological framework. International 597 Journal of Social Research Methodology. 2005;8(1):19-32. 598 35. Levac D, Colquhoun H, O'Brien KK. Scoping studies: advancing the methodology. Implement 599 Sci. 2010;5:69. 600 36. Peters MD, Godfrey CM, Khalil H, McInerney P, Parker D, Soares CB. Guidance for conducting 601 systematic scoping reviews. Int J Evid Based Healthc. 2015;13(3):141-6. 602 37. Tricco AC, Lillie E, Zarin W, O'Brien KK, Colquhoun H, Levac D, et al. PRISMA Extension for 603 Scoping Reviews (PRISMA-ScR): Checklist and Explanation. Ann Intern Med. 2018;169(7):467-73. 604 38. Hanneke R, Asada Y, Lieberman L, Neubauer LC. The Scoping Review Method: Mapping the 605 Literature in "Structural Change" Public Health Interventions. London2017. Available from: 606 https://methods.sagepub.com/case/scoping-review-mapping-literature-structural-change-public-607 interventions. 608 39. Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A. Rayyan-a web and mobile app for

609 systematic reviews. Syst Rev. 2016;5(1):210.

610 40. Gwet KL. Computing inter-rater reliability and its variance in the presence of high 611 agreement. Br J Math Stat Psychol. 2008;61(Pt 1):29-48. 612 Nicholson G, Lehmann B, Padellini T, Pouwels KB, Jersakova R, Lomax J, et al. Improving local 41. 613 prevalence estimates of SARS-CoV-2 infections using a causal debiasing framework. Nature 614 Microbiology. 2022;7(1):97-107. 615 NHS England. 2020/21 National Cost Collection Data Publication 2022 [Available from: 42. 616 https://www.england.nhs.uk/publication/2020-21-national-cost-collection-data-publication/. 617 NICE. Glossary 2023 [Available from: https://www.nice.org.uk/glossary. 43. 618 44. HM Treasury. The Green Book (2022) 2022 [Available from: 619 https://www.gov.uk/government/publications/the-green-book-appraisal-and-evaluation-in-central-620 governent/the-green-book-2020. 621 45. Office C. HMG Baseline Personnel Security Standard. 2018. 622 623 624 625 626 627 628 629 630 631 632 633 634 635 636 637 638

639

## 640 Appendix A: EY-Oxford Health Analytics Consortium Membership (in addition to headline authors)

Name	Affiliation
Adam Bodley	Impact Factor Editing, Oxford
Ainura Moldokmatova	Big Data Institute, Li Ka Shing Centre for Health Information and Discovery, Nuffield
	Department of Medicine, University of Oxford
Anastasiia Polner	Ernst & Young LLP London
Bo Gao	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Caroline Franco	Nuffield Department of Clinical Medicine, University of Oxford   Institute of Theoretical Physics - São Paulo State University (UNESP)
Jared Norman	Modelling and Simulation Hub, Africa (MASHA), University of Cape Town
Katie Douglass	Ernst & Young LLP London
Liberty Cantrell	Department of Paediatrics, University of Oxford
Lok (Joseph) Tsui	Department of Biology, University of Oxford
Ma'ayan Amswych	Ernst & Young LLP London
Muhammad Kasim	Department of Physics, University of Oxford
Randolph Ngwafor Anye	Nuffield Department of Primary Care Health Sciences, University of Oxford
Ricardo Aguas	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Richard Creswell	Department of Computer Science, University of Oxford
Sabine Dittrich	Centre for Tropical Medicine and Global Health Nuffield Department of Medicine, University of Oxford
Sheetal Silal	Centre for Tropical Medicine and Global Health Nuffield Department of Medicine, University of Oxford
Siyu Chen	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Sompob Saralamba	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Sophie Dickenson	Ernst & Young LLP London
Sumali Bajaj	Biodiversity, Ecology & Evolutionary Processes Stream, Department of Biology, University of Oxford
Sunil Pokharel	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Tracy Evans	Nuffield Department of Primary Care Health

	Sciences, University of Oxford
Umar Mahmood	Ernst & Young LLP London
Wirichada Pan-ngum	Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford
Zoe Echanah	Ernst & Young LLP London